The understanding of mastitis, its cause, and the rationale for treatment or nontreatment of mastitis under various circumstances continues to evolve. This article presents research-based evidence about the use or nonuse of drugs to treat mastitis. Nondrug factors involved in decision making about mastitis, including cow characteristics and the epidemiology of mastitis, are also briefly discussed. This article provides information that helps in the making of knowledgeable, evidence-based decisions about therapy for mastitis. Focus is primarily on the use of antimicrobial drugs.
A clinical trial to evaluate the effectiveness of antibiotic treatment of lactating cows with high somatic cell counts in their milk
Use of antimicrobial susceptibility testing of bacterial pathogens isolated from the milk of dairy cows with clinical mastitis to predict response to treatment with cephapirin and oxytetracycline
A comparative field trial of cephalonium and cloxacillin for dry cow therapy for mastitis in Australian dairy cows
Relationship between antimicrobial susceptibility of clinical mastitis pathogens and treatment outcome in cows
Therapeutic effects of systemic or intramammary antimicrobial treatment of bovine subclinical mastitis during lactation
Using dairy herd improvement records and clinical mastitis history to identify subclinical mastitis infections at dry-off
A comparison of broad-spectrum and narrow-spectrum dry cow therapy used alone and in combination with a teat sealant
Decision tree analysis of treatment strategies for mild and moderate cases of clinical mastitis occurring in early lactation
The selective treatment of clinical mastitis based on on-farm culture results: I. Effects on antibiotic use, milk withholding time, and short-term clinical and bacteriological outcomes
Milk yield and somatic cell count during the following lactation after selective treatment of cows at dry-off
Randomized clinical trial to evaluate the efficacy of a 5-day ceftiofur hydrochloride intramammary treatment on nonsevere gram-negative clinical mastitis
Invited review: Mastitis in dairy heifers: nature of the disease, potential impact, prevention, and control
Evaluation of a 3M Petrifilm on-farm culture system for the detection of intramammary infection at the end of lactation
Randomized noninferiority clinical trial evaluating 3 commercial dry cow mastitis preparations: I. Quarter-level outcomes
The effect of internal teat sealant products (Teatseal and Orbeseal) on intramammary infection, clinical mastitis, and somatic cell counts in lactating dairy cows: a meta-analysis
Evaluation of selective dry cow treatment following on-farm culture: risk of postcalving intramammary infection and clinical mastitis in the subsequent lactation
Hot topic: Early postpartum treatment of commercial dairy cows with nonsteroidal antiinflammatory drugs increases whole-lactation milk yield
The Lactococcus genus as a potential emerging mastitis pathogen group: A report on an outbreak investigation
Staphylococcus aureus and Lipopolysaccharide Modulate Gene Expressions of Drug Transporters in Mouse Mammary Epithelial Cells Correlation to Inflammatory Biomarkers
Evaluation of an On-Farm Culture System (Accumast) for Fast Identification of Milk Pathogens Associated with Clinical Mastitis in Dairy Cows
Diagnostic accuracy of a standardized scheme for identification of Streptococcus uberis in quarter milk samples: A comparison between conventional bacteriological examination, modified Rambach agar medium culturing, and 16S rRNA gene sequencing
Evaluation of the biofilm forming ability and its associated genes in Staphylococcus species isolates from bovine mastitis in Argentinean dairy farms
Effect of gradual or abrupt cessation of milking at dry off on milk yield and somatic cell score in the subsequent lactation
Efficacy assessment of an intramammary treatment with a new recrystallized enrofloxacin vs ceftiofur and parenteral enrofloxacin in dairy cows with nonsevere clinical mastitis
Short communication: Increased somatic cell count is associated with milk loss and reduced feed efficiency in lactating dairy cows
Efficacy of recombinant bovine epidermal growth factor in the treatment of experimental subclinical Staphylococcus aureus mastitis in a ewe model
Causes, types, etiological agents, prevalence, diagnosis, treatment, prevention, effects on human health and future aspects of bovine mastitis
Multidrug residues and antimicrobial resistance patterns in waste milk from dairy farms in Central California
Short communication: Staphylococcus aureus infection modulates expression of drug transporters and inflammatory biomarkers in mouse mammary gland
Bacteriophages and their derivatives for the treatment and control of food-producing animal infections
Identification of bovine-associated coagulase-negative staphylococci by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry using a direct transfer protocol
Within-herd prevalence of intramammary infection caused by Mycoplasma bovis and associations between cow udder health, milk yield, and composition
Invited review: Microbiota of the bovine udder: Contributing factors and potential implications for udder health and mastitis susceptibility
Short communication: Diagnosis and classification of clinical and subclinical mastitis utilizing a dynamometer and a handheld infrared thermometer
Histopathological and microbiological findings in buffalo chronic mastitis: evidence of tertiary lymphoid structures
The value of the biomarkers cathelicidin, milk amyloid A, and haptoglobin to diagnose and classify clinical and subclinical mastitis.
Efficacy Prediction of Four Pharmaceutical Formulations for Intramammary Administration Containing Aloe vera (L.) Burm. f. Combined With Ceftiofur or Cloxacillin in Lactating Cows as an Alternative Therapy to Treat Mastitis Caused by Staphylococcus aureus.
Precision Technologies to Address Dairy Cattle Welfare: Focus on Lameness, Mastitis and Body Condition.
A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here
Cellulitis (erysipelas) is a recurring and debilitating bacterial infection of the skin and underlying tissue. Discover the latest research on cellulitis here.